PneumoNP was a collaborative research program funded under the Seventh Framework Programme, with a €5.7 million grant.
Ending in 2017, it aimed at the development of a theragnostic system for the treatment of Gram-negative bacterial infections of the lung, with focus on Klebsiella pneumoniae caused infections.
The main objective of the project was the development of a theragnostic system for the treatment of resistant Gram-negative bacterial infections in lungs.
A majority of international stakeholders from the healthcare sector agree that infections due to antibiotic resistant Gram-negative bacteria are one of the major issues currently affecting global health, largely due to a lack of effective antibiotic therapy for this type of infection. The PneumoNP team has therefore specifically focused its attention on the pathogen Klebsiella pneumoniae, a global cause of antibiotic resistant infections.
PneumoNP aimed to generate:
- a new inhalable drug system composed of a nanotherapeutic system combining an antimicrobial peptide or active pharmaceutical ingredient (API) and a nanocarrier;
- a new aerosol technology specifically developed for the nanotherapeutic system;
- an innovative efficiency-efficacy test to follow-up the treatment;
- a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections.
PneumoNP was a large scale cooperative project, involving 11 partners and lasting 48 months. The work plan has been divided into 8 Work Packages (WPs), including research, technology and development, management, dissemination and exploitation activities.